HRP20240189T1 - Postupak i komplet za utvrđivanje odumiranja stanica ili tkiva ili tkivnog ili staničnog podrijetla dnk-a analizom metilacije dnk-a - Google Patents
Postupak i komplet za utvrđivanje odumiranja stanica ili tkiva ili tkivnog ili staničnog podrijetla dnk-a analizom metilacije dnk-a Download PDFInfo
- Publication number
- HRP20240189T1 HRP20240189T1 HRP20240189TT HRP20240189T HRP20240189T1 HR P20240189 T1 HRP20240189 T1 HR P20240189T1 HR P20240189T T HRP20240189T T HR P20240189TT HR P20240189 T HRP20240189 T HR P20240189T HR P20240189 T1 HRP20240189 T1 HR P20240189T1
- Authority
- HR
- Croatia
- Prior art keywords
- tissue
- cell
- dna
- type
- sequence
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 230000007067 DNA methylation Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 20
- 210000001519 tissue Anatomy 0.000 claims 20
- 230000011987 methylation Effects 0.000 claims 13
- 238000007069 methylation reaction Methods 0.000 claims 13
- 108091092356 cellular DNA Proteins 0.000 claims 11
- 108020004414 DNA Proteins 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 4
- 102000053602 DNA Human genes 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000004958 brain cell Anatomy 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 210000002907 exocrine cell Anatomy 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (9)
1. Postupak otkrivanja odumiranja određene vrste stanice ili tkiva u ispitanika koji sadrži određivanje potječe li nestanična DNK sadržana u uzorku krvi ispitanika od te vrste stanice ili tkiva, pri čemu na navedeno određivanje utječe utvrđivanje statusa metilacije najmanje četiriju mjesta metilacije na kontinuiranoj sekvenci na istoj molekuli nestanične DNK, pri čemu navedena sekvenca ne sadrži više od 300 nukleotida, pri čemu status metilacije svakog od navedenih barem četiriju mjesta metilacije na navedenoj kontinuiranoj sekvenci navedene iste molekule DNK-a karakteristične za navedenu vrstu stanice ili tkiva ukazuje na odumiranje te vrste stanice ili tkiva.
2. Postupak određivanja potječe li DNK iz vrste stanice ili tkiva koji se promatraju u uzorku, pri čemu postupak sadrži:
utvrđivanje statusa metilacije najmanje četiriju mjesta metilacije na kontinuiranoj sekvenci na istoj molekuli DNK-a, pri čemu navedena sekvenca ne sadrži više od 300 nukleotida, pri čemu status metilacije svakog od navedenih barem četiriju mjesta metilacije na navedenoj kontinuiranoj sekvenci iste molekule DNK-a ukazuje na to da DNK potječe od vrste stanice ili tkiva koji se promatraju.
3. Postupak prema zahtjevu 1 ili 2, pri čemu
a. navedeni status metilacije karakterističan je za zdravu vrstu stanice ili tkivo koji se promatraju;
b. navedena sekvenca sadrži između 50 i 250 nukleotida;
c. navedena vrsta stanice ili tkivo ljudska je vrsta stanice ili ljudsko tkivo;
d. navedena vrsta stanice odabrana je iz skupine koja se sastoji od beta stanice gušterače, egzokrine stanice gušterače, hepatocita, moždane stanice, plućne stanice, stanice maternice, bubrežne stanice, stanice dojke, adipocita, stanice debelog crijeva, stanice rektuma, kardiomiocita, stanice skeletnih mišića, stanice prostate i stanice štitnjače; ili
e. navedeno tkivo odabrano je iz skupine koja se sastoji od tkiva gušterače, tkiva jetre, tkiva pluća, moždanog tkiva, tkiva maternice, bubrežnog tkiva, tkiva dojke, masnog tkiva, tkiva debelog crijeva, tkiva rektuma, srčanog tkiva, tkiva skeletnih mišića, tkiva prostate i tkiva štitnjače.
4. Postupak prema zahtjevu 2, pri čemu je navedena DNK nestanična DNK ili stanična DNK.
5. Postupak prema zahtjevu 2, pri čemu uzorak sadrži tjelesnu tekućinu ili se radi o uzorku krvi.
6. Postupak prema zahtjevu 5, pri čemu je navedena tjelesna tekućina odabrana iz skupine koja se sastoji od krvi, plazme, sperme, mlijeka, mokraće, sline i cerebrospinalne tekućine.
7. Postupak prema zahtjevu 1 – 2, 4 i 5, pri čemu na navedeno utvrđivanje ili određivanje utječe:
a. uporaba barem jednog oligonukleotida ovisnog o metilaciji;
b. uporaba oligonukleotida neovisnog o metilaciji;
c. uporaba barem dvaju oligonukleotida neovisnih o metilaciji;
d. uporaba višestruke reakcije; ili
e. sljedeće:
(i) izlaganje DNK-a u uzorku bisulfitu da bi se demetilirani citozini iz DNK-a konvertirali u uracile;
(ii) klonska amplifikacija navedene kontinuirane sekvence DNK-a s pomoću oligonukleotida koji hibridiziraju u sekvencu nukleinske kiseline koja je spojena s prvim i zadnjim od navedenih barem četiriju mjesta metilacije na navedenoj kontinuiranoj sekvenci DNK-a; i
(iii) sekvenciranje navedene klonski amplificirane kontinuirane sekvence DNK-a.
8. Postupak prema zahtjevu 1 ili 4, pri čemu uzorak sadrži nestaničnu DNK koja potječe iz druge stanice koja nije identična navedenoj vrsti stanice ili tkivu.
9. Postupak prema zahtjevu 8, koji nadalje sadrži analiziranje količine nestanične DNK koja potječe iz navedene vrste stanice ili tkiva, odnosno količine nestanične DNK koja potječe iz navedene druge stanice, ili analiziranje količine nestanične DNK koja potječe iz navedene vrste stanice ili tkiva, odnosno ukupne količine nestanične DNK u uzorku; ili sadrži analiziranje količine nestanične DNK koja potječe iz navedene vrste stanice ili tkiva, odnosno ukupne količine nestanične DNK u uzorku.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979233P | 2014-04-14 | 2014-04-14 | |
| EP22158931.0A EP4026917B1 (en) | 2014-04-14 | 2015-04-14 | A method and kit for determining the death of cells or tissue or the tissue or cell origin of dna by dna methylation analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240189T1 true HRP20240189T1 (hr) | 2024-04-26 |
Family
ID=53051869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240189TT HRP20240189T1 (hr) | 2014-04-14 | 2015-04-14 | Postupak i komplet za utvrđivanje odumiranja stanica ili tkiva ili tkivnog ili staničnog podrijetla dnk-a analizom metilacije dnk-a |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11203784B2 (hr) |
| EP (4) | EP3132055A2 (hr) |
| JP (1) | JP6750879B2 (hr) |
| CN (1) | CN106574296B (hr) |
| DK (2) | DK3643795T3 (hr) |
| ES (1) | ES2974838T3 (hr) |
| FI (1) | FI4026917T3 (hr) |
| HR (1) | HRP20240189T1 (hr) |
| IL (1) | IL248299B (hr) |
| LT (1) | LT4026917T (hr) |
| PL (1) | PL4026917T3 (hr) |
| PT (1) | PT4026917T (hr) |
| SI (1) | SI4026917T1 (hr) |
| WO (2) | WO2015159292A2 (hr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| EP3842551B1 (en) | 2012-09-04 | 2023-11-01 | Guardant Health, Inc. | Methods of analysing cell free polynucleotides |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
| EP3132055A2 (en) | 2014-04-14 | 2017-02-22 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
| HUE056267T2 (hu) | 2014-07-18 | 2022-02-28 | Univ Hong Kong Chinese | DNS-keverékek szöveteinek metilációs mintázatelemzése |
| EP3325663B1 (en) | 2015-07-20 | 2020-08-19 | The Chinese University Of Hong Kong | Methylation pattern analysis of haplotypes in tissues in dna mixture |
| WO2017106768A1 (en) | 2015-12-17 | 2017-06-22 | Guardant Health, Inc. | Methods to determine tumor gene copy number by analysis of cell-free dna |
| US20190085406A1 (en) | 2016-04-14 | 2019-03-21 | Guardant Health, Inc. | Methods for early detection of cancer |
| US11384382B2 (en) | 2016-04-14 | 2022-07-12 | Guardant Health, Inc. | Methods of attaching adapters to sample nucleic acids |
| CA3023335A1 (en) * | 2016-05-04 | 2017-11-30 | Queen's University At Kingston | Cell-free detection of methylated tumour dna |
| CA3025708A1 (en) | 2016-05-30 | 2017-12-07 | The Chinese University Of Hong Kong | Detecting hematological disorders using cell-free dna in blood |
| EP3464644A4 (en) * | 2016-06-07 | 2020-07-15 | The Regents of The University of California | PATTERNS OF ACELLULAR DNA METHYLATION FOR ANALYSIS OF DISEASES AND CONDITIONS |
| CN109890977A (zh) | 2016-08-17 | 2019-06-14 | 加利福尼亚大学董事会 | 通过基于生物流体的无细胞dna(cfdna)测定评价器官损伤状态的基于免疫探针的新方法 |
| US11959125B2 (en) * | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| AU2017347790B2 (en) | 2016-10-24 | 2024-06-13 | Grail, Inc. | Methods and systems for tumor detection |
| EP3548632A4 (en) | 2016-11-30 | 2020-06-24 | The Chinese University Of Hong Kong | ANALYSIS OF CELLULAR DNA IN URINE AND OTHER SAMPLES |
| MX2019007444A (es) | 2016-12-22 | 2019-08-16 | Guardant Health Inc | Metodos y sistemas para analisis de moleculas de acido nucleico. |
| US10633713B2 (en) | 2017-01-25 | 2020-04-28 | The Chinese University Of Hong Kong | Diagnostic applications using nucleic acid fragments |
| WO2018187521A2 (en) | 2017-04-06 | 2018-10-11 | Cornell University | Methods of detecting cell-free dna in biological samples |
| CN111032868A (zh) * | 2017-06-30 | 2020-04-17 | 加利福尼亚大学董事会 | 用于评估无细胞dna中的dna甲基化的方法和系统 |
| EP3652342A1 (en) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Detecting tissue-specific dna |
| WO2019012544A1 (en) | 2017-07-13 | 2019-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | STRATEGY FOR DOUBLE PROBE DROPLETS FOR SPECIFIC DETECTION OF CIRCULATING DNA MOLECULES SPECIFIC TO A TISSUE |
| EP4403646A3 (en) | 2017-07-13 | 2025-01-08 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna targets as tissue-specific methylation markers |
| DE102017126248B4 (de) * | 2017-11-09 | 2019-10-17 | Epiontis Gmbh | ERGIC1 als epigenetischer Marker zur Identifizierung von Immunzellen, insbesonderemonozytischem myeloid-abgeleiteten Suppressor-Zellen (mMDSCs) |
| WO2019159184A1 (en) * | 2018-02-18 | 2019-08-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Cell free dna deconvolution and use thereof |
| EP3765638A2 (en) * | 2018-03-13 | 2021-01-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Diagnostic use of cell free dna chromatin immunoprecipitation |
| TWI834642B (zh) | 2018-03-13 | 2024-03-11 | 美商格瑞爾有限責任公司 | 異常片段偵測及分類 |
| JP7620803B2 (ja) * | 2018-03-15 | 2025-01-24 | グレイル インコーポレイテッド | 組織特異的メチル化マーカー |
| CN112236520B (zh) | 2018-04-02 | 2025-01-24 | 格里尔公司 | 甲基化标记和标靶甲基化探针板 |
| WO2019209884A1 (en) | 2018-04-23 | 2019-10-31 | Grail, Inc. | Methods and systems for screening for conditions |
| JP2021112127A (ja) * | 2018-04-26 | 2021-08-05 | 暁生 黒田 | 膵β細胞の傷害検査方法 |
| WO2019232435A1 (en) | 2018-06-01 | 2019-12-05 | Grail, Inc. | Convolutional neural network systems and methods for data classification |
| CN113286881A (zh) | 2018-09-27 | 2021-08-20 | 格里尔公司 | 甲基化标记和标靶甲基化探针板 |
| KR20210141915A (ko) | 2018-11-21 | 2021-11-23 | 아비다 바이오메드 인코포레이티드 | 표적화된 핵산 라이브러리 형성을 위한 방법 |
| US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
| WO2020132148A1 (en) * | 2018-12-18 | 2020-06-25 | Grail, Inc. | Systems and methods for estimating cell source fractions using methylation information |
| WO2020155149A1 (en) * | 2019-02-02 | 2020-08-06 | Lenovo (Beijing) Limited | Enhanced scheduling of time sensitive networking |
| IL265451B (en) | 2019-03-18 | 2020-01-30 | Frumkin Dan | Methods and systems for the detection of methylation changes in DNA samples |
| US20220064731A1 (en) * | 2019-04-03 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Primers for multiplex pcr |
| US11773450B2 (en) | 2019-04-03 | 2023-10-03 | Grail, Llc | Methylation-based false positive duplicate marking reduction |
| US11001898B2 (en) | 2019-05-31 | 2021-05-11 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
| US11396679B2 (en) | 2019-05-31 | 2022-07-26 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
| CN114616343A (zh) | 2019-09-30 | 2022-06-10 | 夸登特健康公司 | 用于在甲基化分区测定中分析无细胞dna的组合物和方法 |
| KR102103885B1 (ko) * | 2019-10-08 | 2020-04-24 | 주식회사 레피다인 | 생물학적 시료의 간 조직 유래 여부를 판별하는 방법 |
| US11898199B2 (en) | 2019-11-11 | 2024-02-13 | Universal Diagnostics, S.A. | Detection of colorectal cancer and/or advanced adenomas |
| JP2023513470A (ja) | 2020-01-30 | 2023-03-31 | プログノミック インコーポレイテッド | 肺バイオマーカーおよびそれらの使用方法 |
| CN115103909A (zh) | 2020-01-31 | 2022-09-23 | 艾维达生物医学公司 | 用于靶向核酸捕获的系统和方法 |
| WO2022002424A1 (en) | 2020-06-30 | 2022-01-06 | Universal Diagnostics, S.L. | Systems and methods for detection of multiple cancer types |
| US12007397B2 (en) | 2021-09-13 | 2024-06-11 | PrognomIQ, Inc. | Enhanced detection and quantitation of biomolecules |
| US20230212674A1 (en) * | 2021-12-30 | 2023-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for identifying cell types |
| EP4497139A2 (en) * | 2022-03-15 | 2025-01-29 | Resonant LLC | Neuronal methylation signatures from cell free dna as a pre-symptomatic neurodegenerative condition surveillance diagnostic |
| WO2024038457A1 (en) | 2022-08-18 | 2024-02-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A method for determining the tissue or cell of origin of dna |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| KR100236506B1 (ko) | 1990-11-29 | 2000-01-15 | 퍼킨-엘머시터스인스트루먼츠 | 폴리머라제 연쇄 반응 수행 장치 |
| CA2074214C (en) | 1991-07-23 | 2000-02-22 | Will Bloch | Improvements in the in situ pcr |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5612473A (en) | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| EP1021462A4 (en) * | 1997-10-07 | 2005-04-13 | Merck & Co Inc | TEST FOR CORE RECEPTOR LIGANDS USING FRET |
| US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
| AU2002352143A1 (en) * | 2001-11-23 | 2003-06-10 | Epigenomics Ag | Method and nucleic acids for the analysis of a lymphoid cell proliferative disorder |
| ATE312946T1 (de) * | 2002-03-05 | 2005-12-15 | Epigenomics Ag | Verfahren und vorrichtung zur bestimmung der gewebespezifität von freier dna in körperflüssigkeiten |
| US7709194B2 (en) | 2004-06-04 | 2010-05-04 | The Chinese University Of Hong Kong | Marker for prenatal diagnosis and monitoring |
| ES2570828T3 (es) | 2007-06-08 | 2016-05-20 | Epigenomics Ag | Método de análisis de metilación |
| BRPI1015924A2 (pt) | 2009-07-01 | 2016-04-26 | Sharp Kk | substrato de matriz ativa e dispositivo de exibição el orgânico |
| WO2011101728A2 (en) | 2010-02-19 | 2011-08-25 | Nucleix | Identification of source of dna samples |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| EP2561097A2 (en) | 2010-04-20 | 2013-02-27 | Nucleix | Methylation profiling of dna samples |
| WO2012047091A1 (en) * | 2010-10-08 | 2012-04-12 | Universiti Putra Malaysia | Glp-1 promoter mediated insulin expression for the treatment of diabetes |
| US10125394B2 (en) * | 2011-06-22 | 2018-11-13 | Yale University | Compositions and methods for diagnosing diseases and disorders associated with β cell death |
| US20130129668A1 (en) * | 2011-09-01 | 2013-05-23 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
| US9127317B2 (en) | 2012-03-02 | 2015-09-08 | Winthrop-University Hospital | Method for using probe based PCR detection to measure the levels of circulating demethylated β cell derived DNA as a measure of β cell loss in diabetes |
| JP5962761B2 (ja) | 2012-07-20 | 2016-08-03 | 株式会社村田製作所 | 生体センサ |
| WO2014138133A1 (en) | 2013-03-04 | 2014-09-12 | Islet Sciences, Inc. | Compositions and methods for detecting hypo-methylated dna in body fluids |
| CN105026580A (zh) | 2013-03-15 | 2015-11-04 | 雅培分子公司 | 重亚硫酸盐转化的核苷酸序列的检测 |
| EP3132055A2 (en) | 2014-04-14 | 2017-02-22 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | A method and kit for determining the tissue or cell origin of dna |
| SG11201608993RA (en) | 2014-05-09 | 2016-11-29 | Lifecodexx Ag | Detection of dna that originates from a specific cell-type and related methods |
| US10858706B2 (en) | 2015-07-10 | 2020-12-08 | Nyu Winthrop Hospital | System, method and kit for analysis of circulating differentially methylated DNA as a biomarker of beta-cell loss |
| EP4403646A3 (en) | 2017-07-13 | 2025-01-08 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna targets as tissue-specific methylation markers |
| EP3652342A1 (en) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Detecting tissue-specific dna |
| WO2019012544A1 (en) | 2017-07-13 | 2019-01-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | STRATEGY FOR DOUBLE PROBE DROPLETS FOR SPECIFIC DETECTION OF CIRCULATING DNA MOLECULES SPECIFIC TO A TISSUE |
-
2015
- 2015-04-14 EP EP15720481.9A patent/EP3132055A2/en not_active Ceased
- 2015-04-14 PT PT221589310T patent/PT4026917T/pt unknown
- 2015-04-14 CN CN201580031764.XA patent/CN106574296B/zh active Active
- 2015-04-14 DK DK19209237.7T patent/DK3643795T3/da active
- 2015-04-14 DK DK22158931.0T patent/DK4026917T5/da active
- 2015-04-14 WO PCT/IL2015/050403 patent/WO2015159292A2/en active Application Filing
- 2015-04-14 EP EP23209884.8A patent/EP4306659A3/en active Pending
- 2015-04-14 HR HRP20240189TT patent/HRP20240189T1/hr unknown
- 2015-04-14 LT LTEP22158931.0T patent/LT4026917T/lt unknown
- 2015-04-14 EP EP22158931.0A patent/EP4026917B1/en active Active
- 2015-04-14 FI FIEP22158931.0T patent/FI4026917T3/fi active
- 2015-04-14 PL PL22158931.0T patent/PL4026917T3/pl unknown
- 2015-04-14 ES ES22158931T patent/ES2974838T3/es active Active
- 2015-04-14 US US15/303,762 patent/US11203784B2/en active Active
- 2015-04-14 SI SI201531988T patent/SI4026917T1/sl unknown
- 2015-04-14 WO PCT/IL2015/050404 patent/WO2015159293A2/en active Application Filing
- 2015-04-14 JP JP2016562026A patent/JP6750879B2/ja active Active
- 2015-04-14 EP EP19209237.7A patent/EP3643795B1/en active Active
-
2016
- 2016-10-10 IL IL248299A patent/IL248299B/en active IP Right Grant
-
2021
- 2021-11-17 US US17/528,699 patent/US20220064730A1/en active Pending
-
2023
- 2023-02-15 US US18/169,821 patent/US20230242985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017511142A (ja) | 2017-04-20 |
| DK3643795T3 (da) | 2022-05-09 |
| CN106574296B (zh) | 2021-03-02 |
| PL4026917T3 (pl) | 2024-04-08 |
| IL248299B (en) | 2021-04-29 |
| FI4026917T3 (fi) | 2024-02-14 |
| EP4026917A1 (en) | 2022-07-13 |
| EP4026917B1 (en) | 2023-11-15 |
| US20230242985A1 (en) | 2023-08-03 |
| US20220064730A1 (en) | 2022-03-03 |
| CN106574296A (zh) | 2017-04-19 |
| SI4026917T1 (sl) | 2024-05-31 |
| PT4026917T (pt) | 2024-02-12 |
| EP3643795B1 (en) | 2022-03-30 |
| US11203784B2 (en) | 2021-12-21 |
| IL248299A0 (en) | 2016-11-30 |
| EP4306659A3 (en) | 2024-03-27 |
| WO2015159293A2 (en) | 2015-10-22 |
| WO2015159293A3 (en) | 2015-12-10 |
| ES2974838T3 (es) | 2024-07-01 |
| US20170121767A1 (en) | 2017-05-04 |
| DK4026917T3 (da) | 2024-02-12 |
| WO2015159292A2 (en) | 2015-10-22 |
| WO2015159292A3 (en) | 2015-12-10 |
| LT4026917T (lt) | 2024-03-12 |
| DK4026917T5 (da) | 2024-07-15 |
| EP3132055A2 (en) | 2017-02-22 |
| EP3643795A1 (en) | 2020-04-29 |
| JP6750879B2 (ja) | 2020-09-02 |
| EP4306659A2 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240189T1 (hr) | Postupak i komplet za utvrđivanje odumiranja stanica ili tkiva ili tkivnog ili staničnog podrijetla dnk-a analizom metilacije dnk-a | |
| HRP20210716T1 (hr) | Neinvazivno određivanje metiloma tumora iz plazme | |
| Lee et al. | Genome-wide methylation profiling and a multiplex construction for the identification of body fluids using epigenetic markers | |
| Patel et al. | High resolution of microRNA signatures in human whole saliva | |
| Barbazan et al. | Molecular characterization of circulating tumor cells in human metastatic colorectal cancer | |
| HRP20200764T1 (hr) | Metode za kvantifikaciju cirkulirajuće slobodne dnk | |
| EP3828291A1 (en) | Methylation modification-based tumor marker stamp-ep1 | |
| JP2019520037A5 (hr) | ||
| Arai et al. | Epigenetic assessment of environmental chemicals detected in maternal peripheral and cord blood samples | |
| BR112018013430A2 (pt) | ?métodos para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide e para prognosticar risco de malignidade, e, kit? | |
| RU2014119928A (ru) | Диагностика анэплоидии у плода | |
| WO2014170497A3 (en) | Method for identifying the quantitative cellular composition in a biological sample | |
| US9840742B2 (en) | Detection of hepatitis B virus (HBV) DNA and methylated HBV DNA in urine of patients with HBV-associated hepatocellular carcinoma | |
| EP3904515A1 (en) | Tumor marker stamp-ep3 based on methylation modification | |
| WO2011112903A3 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients | |
| WO2016130572A3 (en) | Methods of determining levels of exposure to radiation and uses thereof | |
| Lee et al. | A collaborative exercise on DNA methylation-based age prediction and body fluid typing | |
| ES2651522T3 (es) | Altos niveles de FT de TEM para el diagnóstico del cáncer, en particular de cáncer colorrectal (CCR) y de páncreas (CP) | |
| US20220195528A1 (en) | Tumor marker stamp-ep5 based on methylated modification | |
| CN108342486A (zh) | 一种膀胱癌znf154、pou4f2、eomes基因的引物及检测试剂盒 | |
| US20220177973A1 (en) | Methylation modification-based tumor marker stamp-ep6 | |
| CN107177676A (zh) | 长链非编码rna nonhsat113026用于肾癌诊断分子标志物的用途 | |
| JP2013526869A5 (hr) | ||
| CN109609620B (zh) | 用于辅助诊断血行播散型肺结核的试剂盒 | |
| Gahan et al. | Circulating Nucleic Acids in Serum and Plasma-CNAPS IX |